Migraine

Individuals taking erenumab had a 55.4% reduction from baseline in their monthly migraine days, results from HER-MES show.

Ten quiz questions to assess your knowledge on common symptoms and treatments for migraine headaches.

Atogepant is indicated for the preventive treatment of episodic migraine in adults.

Significant reductions in mean monthly migraine days compared with placebo were seen as early as weeks 1 through 4 in the clinical trial program for atogepant.

Migraine headaches can be caused by triggers such as hormonal changes, drinks, stress, sensory stimuli, sleep changes, physical factors, weather changes, medications, foods, and food additives.

The nasal spray bypasses the gut and potential absorption issues associated with it, and offers consistent relief even when administered hours after the onset of a migraine attack.

A greater proportion of atogepant-treated participants achieved at least a 50% reduction in mean monthly migraine days.

Peptides that cause migraine pain can influence insulin production in mice, possibly by regulating the amount of secreted insulin or by increasing the number of pancreatic cells that produce it.

Erenumab was found to have a sustained efficacy as a monotherapy treatment for episodic migraine that was found to not respond to 2 to 4 prior preventive treatments.

This recurring condition can require more firepower than OTC pain medications offer.

The human monoclonal antibody helps treat the painful and often debilitating condition.

Emgality (Galcanezumab-gnlm) is a self-administered once monthly subcutaneous injection and the third in its class for the preventative treatment of migraine in adults.

Amgen and Novartis have announced positive long-term efficacy, safety, and tolerability data of erenumab-aooe (Aimovig) in patients with chronic and episodic migraine.

Erenumab-aooe (Aimovig, Amgen) is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of the molecule that is involved in migraine attacks.

Erenumab-aooe (Aimovig, Amgen) is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of the molecule that is involved in migraine attacks.

Thirty two million Americans are affected by migraines, and women are affected 3 times more than men.

Amgen’s erenumab (Aimovig) achieved positive results in the first-of-its-kind phase 3b LIBERTY trial for the treatment of patients with episodic migraines who had previously failed 2 to 4 preventive treatments.

Patients treated with erenumab had nearly 3-fold higher odds of having their migraine days cut by at least 50%.